SYK · Healthcare

STRYKER CORP

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-08

• Impairment ChargesImportance 36 · Surprise 42
  A third-party report published November 8, 2026, noted that Stryker recorded a US$293 million goodwill impairment in connection with its Q3 earnings. The reported amount exceeds the specified materiality threshold of…

News · 2026-11-07

• Guidance / OutlookImportance 47 · Surprise 60
  Third-party reporting says Stryker lowered its 2026 organic sales-growth forecast. The reported reasons were slower hip and knee procedures and broader economic pressures. The article does not specify the revised…
• Revenue Performance and MixImportance 40 · Surprise 14
  Stryker’s third-quarter revenue grew 7.7% year over year to $6.5 billion. The digest does not provide segment revenue figures or a sequential growth rate. The reported 7.7% increase represents roughly $465 million…
• Procedure Volume TrendsImportance 20 · Surprise 24
  Third-party reporting said Stryker faced slower hip and knee procedures. The slowdown was cited as a factor behind weaker expected organic sales growth, although the outlook itself is excluded from this analysis. No…
• Net Income and EPS PerformanceImportance 19 · Surprise 22
  Stryker’s third-quarter net earnings fell 12.3% year over year. The digest does not state the net earnings amount or earnings per share. The reported decline exceeded the 10% change threshold for inclusion.

News · 2026-11-06

• Net Income and EPS PerformanceImportance 78 · Surprise 74
  Third-party analysis reported that unusual, likely one-off items reduced Stryker’s profit by US$897 million. It characterized the expenses as potentially nonrecurring, which could lift profit in the coming year if they…
• Manufacturing And CapacityImportance 25 · Surprise 42
  Third-party reporting cited recent manufacturing disruptions in Stryker’s Peripheral Vascular unit. The article did not quantify the disruptions’ effect on output, capacity, or customer deliveries. It said the issues…
• Market Demand TrendsImportance 17 · Surprise 24
  Third-party reporting described softer conditions in key joint replacement markets, indicating weaker demand in that product area. It also linked the demand softness to potential effects on the timing and level of…

News · 2026-11-05

• Supply Chain and Cybersecurity ImpactImportance 33 · Surprise 42
  A March 2026 cyberattack targeting Stryker’s Microsoft IT network wiped data and shut down manufacturing for weeks. The disruption forced patient procedures to be rescheduled, indicating operational impacts extending…

News · 2026-11-04

• Revenue Performance and MixImportance 24 · Surprise 14
  Stryker reported quarterly revenue of $6.52 billion, $100 million below the $6.62 billion consensus estimate. Revenue increased 7.6% year over year, equivalent to approximately $460 million of growth from the…

News · 2026-11-03

• Revenue Performance and MixImportance 62 · Surprise 68
  Stryker reported third-quarter sales of $6.52 billion, below analyst expectations. The quarter was affected by cyberattack pressures, an SAP transition, and supply disruptions. Stryker lowered its full-year 2026…
• Guidance / OutlookImportance 62 · Surprise 68
  Third-party reporting says Stryker lowered its 2026 organic sales growth forecast to 6.5%–7.0%. The reported slowdown reflects broader market deceleration and slower market-share gains in Orthopaedics, including hips…
• Acquisition / Partnership / DivestitureImportance 58 · Surprise 42
  Stryker is investing approximately US$400 million in UK surgical robotics developer CMR Surgical. The agreement gives Stryker an exclusive option to acquire CMR Surgical’s remaining equity and exclusive US commercial…
• Competition and Market PositionImportance 20 · Surprise 24
  Stryker’s Orthopaedics division, including its hip and knee businesses, is experiencing slower revenue growth than the rest of the company amid a general market deceleration. The report says Stryker has been unable to…

News · 2026-11-02

• Guidance / OutlookImportance 44 · Surprise 60
  Stryker revised its outlook because supply chain disruptions caused by a cyber attack were still affecting the company, according to reporting published November 2, 2026. The report did not specify the revised revenue…
• Supply Chain and Cybersecurity ImpactImportance 37 · Surprise 42
  Stryker is experiencing ongoing supply chain disruptions caused by a cyber attack. The report attributes the disruptions to the cyber attack but gives no detail on affected products, manufacturing sites, or customers.…

News · 2026-11-01

• Guidance / OutlookImportance 56 · Surprise 68
  Third-party reporting said Stryker lowered its full-year adjusted EPS guidance to a midpoint of $14.85. The revised midpoint represented a 1.2% decrease. The change was reported following the company’s Q3 2026 results.
• Operating Income and MarginsImportance 36 · Surprise 40
  Stryker’s Q3 2026 operating margin was 15.9%, compared with 18.7% in the same quarter of 2025. The 2.8-percentage-point decline represents a relative margin decrease of about 15% year over year.
• Revenue Performance and MixImportance 24 · Surprise 14
  Stryker reported Q3 2026 revenue of $6.52 billion, up 7.6% year over year and $100 million below analysts’ $6.62 billion estimate. Organic revenue grew 7.7% year over year, also below expectations.
• Market Demand TrendsImportance 17 · Surprise 24
  Third-party reporting characterized Stryker’s orthopedics performance in Q3 2026 as soft. The report did not quantify the weakness or identify specific product categories or geographies driving it. It also referenced…

News · 2026-10-31

• Guidance / OutlookImportance 47 · Surprise 60
  Third-party reporting says Stryker cut its full-year 2026 guidance after reporting third-quarter results. The report does not provide the previous or revised guidance figures, or quantify the size of the reduction. It…
• Impairment ChargesImportance 40 · Surprise 42
  Stryker recorded a $293 million goodwill impairment in its third-quarter 2026 results. The impairment exceeded the stated $196 million materiality threshold. The report described the write-down as a sizeable charge…
• Revenue Performance and MixImportance 34 · Surprise 14
  Stryker reported third-quarter 2026 sales of $6.52 billion, up 7.7% year over year. Third-quarter sales were also reported as US$6.52 billion. Softer hip and knee procedure volumes were identified as pressures within…
• Net Income and EPS PerformanceImportance 29 · Surprise 22
  Stryker reported third-quarter 2026 net income of $753 million, down 12.3% year over year. Reported earnings per share fell 11.7% to $1.96. The third-party report said Stryker’s results missed internal targets.
• Procedure Volume TrendsImportance 20 · Surprise 24
  Third-party reporting identified softer hip and knee procedure volumes as a demand pressure for Stryker. The report did not quantify the change in procedure volumes or specify a geography. It described weaker…

10-Q · 2026-10-30

• Income Tax Rate ChangesImportance 60 · Surprise 74
  The effective tax rate was 24.5% in the third quarter of 2026, compared with 16.5% in the third quarter of 2025.,For the first nine months, the effective tax rate increased to 18.7% from 14.7%.,The third-quarter increase was attributed to the nondeductible $293 million goodwill impairment related to Peripheral Vascular.,The nine-month rate increase reflected the nondeductible goodwill impairment and the prior-year tax benefit associated with the sale of the Spinal Implants business.
• Gross Margin DriversImportance 54 · Surprise 40
  Third-quarter gross profit rose to $4,248 million from $3,852 million, and gross margin increased to 65.2% from 63.6%.,Quarterly margin improvement reflected 60 basis points from volume and mix and 100 basis points from lower amortization of inventory stepped up to fair value; manufacturing and supply-chain costs reduced margin by 20 basis points.,Nine-month gross profit was $12,556 million versus $11,437 million, and gross margin increased to 65.6% from 63.7%.,Nine-month margin benefited from a 90-basis-point reversal of 2025 tariffs and 90 basis points from lower inventory step-up amortization, partly offset by an 80-basis-point increase in manufacturing and supply-chain costs, primarily tied to idle production time from the first-quarter 2026 cybersecurity incident.
• Operating Expense TrendsImportance 54 · Surprise 40
  Third-quarter selling, general and administrative expense increased $268 million, or 13.1%, to $2,313 million, and rose to 35.5% of sales from 33.8%, primarily because of higher structural optimization and other special charges.,Nine-month SG&A increased $399 million, or 6.2%, to $6,823 million, while its sales ratio was nearly flat at 35.7% versus 35.8%.,Nine-month research, development and engineering expense increased $58 million, or 4.7%, to $1,280 million; it was 6.7% of sales compared with 6.8% a year earlier.,Higher nine-month structural optimization and other special charges were offset by lower acquisition and integration-related costs.
• Operating Income and MarginsImportance 54 · Surprise 40
  Third-quarter operating income was $1,034 million, down from $1,135 million, and operating margin fell to 15.9% from 18.7%.,Nine-month operating income increased to $3,629 million from $3,085 million, with operating margin rising to 19.0% from 17.2%.,Third-quarter MedSurg and Neurotechnology operating margin rose to 28.7% from 26.1%, primarily due to lower SG&A, lower manufacturing and supply-chain costs, and higher unit volumes.,Third-quarter Orthopaedics operating margin declined to 31.2% from 32.4%, as higher SG&A and manufacturing and supply-chain costs partly offset higher unit volumes.
• Supply Chain ConstraintsImportance 52 · Surprise 42
  Stryker reported that Peripheral Vascular operating results were affected by near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery. The company’s…
• Other Income (Expense), NetImportance 51 · Surprise 64
  Other income increased to $106 million in the third quarter of 2026 from $51 million a year earlier, a 107.8% increase.,Nine-month other income rose to $214 million from $177 million, a 20.9% increase.,The increases in both periods were primarily due to income from intellectual-property licensing in 2026.
• Revenue Performance and MixImportance 49 · Surprise 32
  Third-quarter 2026 net sales increased 7.7% to $6,520 million, with constant-currency growth of 7.6% driven by unit volume and 0.1% by higher prices.,Nine-month 2026 net sales increased 6.6% to $19,129 million; constant-currency growth was 5.9%, and organic constant-currency growth was 6.2% after excluding a 0.5% acquisition and divestiture impact.,MedSurg and Neurotechnology sales grew 9.2% in the quarter and 8.0% for nine months, while Orthopaedics sales grew 5.7% and 4.9%, respectively.,For the nine months, U.S. sales increased 6.0% to $14,385 million and international sales increased 8.3% to $4,744 million.
• Market Demand TrendsImportance 49 · Surprise 32
  Consolidated net sales increased 7.7% in the third quarter and 6.6% for the first nine months of 2026. Growth was primarily volume-driven, with higher product shipments across all MedSurg and Neurotechnology businesses…
• Balance Sheet and LiquidityImportance 46 · Surprise 30
  Cash, cash equivalents, short-term investments and marketable securities totaled $3,271 million at September 30, 2026, down from $4,100 million at December 31, 2025.,Current assets exceeded current liabilities by $7,683 million at September 30, 2026, compared with $6,961 million at December 31, 2025.,Cash, cash equivalents, short-term investments and marketable securities held outside the United States represented approximately 44% of the total at September 30, 2026, versus 20% at December 31, 2025.,Nine-month operating cash flow increased to $3,303 million from $2,901 million, primarily because higher net earnings were partly offset by working-capital changes.
• Geographic Market CommentaryImportance 43 · Surprise 32
  United States sales increased 8.3% in the third quarter and 6.0% for the first nine months of 2026. International sales increased 5.7% in the quarter and 8.3% year to date as reported; constant-currency growth was 6.0%…
• Acquisition / Partnership / DivestitureImportance 34 · Surprise 42
  Stryker completed the acquisition of AVS during the first nine months of 2026, and the period’s investing cash flows included the net cash consideration paid for the acquisition.,Nine-month investing activities used $1,011 million in cash, compared with $4,561 million in the prior-year period.,The filing also identifies the prior-year acquisition of Inari and the sale of the Spinal Implants business; the Spinal Implants sale generated a tax benefit that affected the nine-month effective tax-rate comparison.
• Guidance / OutlookImportance 33 · Surprise 24
  Management expects segment mix to have an unfavorable impact on gross margin for the foreseeable future. This outlook reflects anticipated faster sales growth in the lower-gross-margin MedSurg and Neurotechnology…
• Capital Return ProgramImportance 26 · Surprise 24
  Stryker repurchased $1,000 million of common stock during the first nine months of 2026.,Financing activities used $2,998 million of cash in the 2026 nine-month period, with the use of cash primarily driven by $1,000 million of repayments for maturing unsecured notes, common-stock repurchases, and dividend payments.,Financing activities provided $1,206 million in the prior-year nine-month period, primarily from issuance of senior unsecured notes, partly offset by dividend payments.

News · 2026-10-30

• Guidance / OutlookImportance 63 · Surprise 60
  Stryker lowered its 2026 organic net sales growth outlook to 6.5%–7%. The company attributed the reduction to an unexpected slowdown in hip and knee replacement procedures, weaker-than-expected performance, and…
• Acquisition / Partnership / DivestitureImportance 58 · Surprise 42
  Stryker agreed to invest approximately $400 million in CMR Surgical, an amount above the stated materiality threshold. The agreement makes Stryker the exclusive U.S. distributor of CMR’s Versius Plus surgical robot.…
• Capital Return ProgramImportance 52 · Surprise 42
  Stryker repurchased $1 billion of common stock during the reported period. The company approved an additional $3 billion for its share repurchase program. The reported authorization increases the amount available for…
• Revenue Performance and MixImportance 36 · Surprise 14
  Stryker reported third-quarter 2026 revenue of $6.52 billion, up 7.7% year over year, but 0.9% below the Zacks consensus estimate of $6.57 billion. Organic sales increased 9.1% in MedSurg and Neurotechnology and 5.9%…
• Products and TechnologyImportance 34 · Surprise 42
  Stryker is preparing to scale CMR Surgical’s Versius Plus surgical robot in the United States. The company is described as the robot’s exclusive U.S. distributor, providing a route to expand its presence in surgical…
• Spine Impairment and CompetitionImportance 28 · Surprise 42
  Stryker recorded a $293 million goodwill impairment charge related to its Peripheral Vascular business in the third quarter of 2026. The charge was reported with the company’s third-quarter filing. Third-quarter…
• Market Demand TrendsImportance 26 · Surprise 24
  Stryker reported an unexpected slowdown in U.S. hip and knee replacement procedures, with higher insurance premiums and deductibles and more pre-authorization denials contributing to weaker patient access. In the third…
• Net Income and EPS PerformanceImportance 23 · Surprise 22
  Third-quarter 2026 adjusted earnings were $3.52 per share, up 10.3% year over year, but missed the Zacks consensus estimate of $3.56 by 1.1%. GAAP EPS declined 11.7% to $1.96 year over year. The reported adjusted EPS…
• Supply Chain and Cybersecurity ImpactImportance 20 · Surprise 24
  Third-party reports identified peripheral vascular supply disruptions and constraints as factors weighing on Stryker’s performance. A separate report also cited cyber issues alongside supply constraints, but the digest…

Earnings call · 2026-10-29

• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Stryker’s Peripheral Vascular joint venture in China generated one-time Q3 revenue after reaching a regulatory approval milestone in September. Management said it expects FDA approval of AVS’s IVL product toward the…
• Soft Tissue Augmentation ProductImportance 34 · Surprise 42
  Management described ZuriMED’s FiberLocker technology as a differentiated soft-tissue augmentation product with an open system that can attach different materials and an applicator it considers particularly effective.…
• Market Demand TrendsImportance 32 · Surprise 24
  Management estimates the hip and knee replacement market is growing about 2.5% year to date, a step down from growth in recent years, and says it slowed further in the third quarter. In the U.S., affordability concerns…
• Capital Demand and CapacityImportance 32 · Surprise 24
  Management described capital demand as strong and the order book as elevated, with demand healthy across businesses. It said the company is focused on executing against that demand by matching production and supply to…
• Competition and Market PositionImportance 32 · Surprise 24
  Management said it has not been winning in hips and knees at its historical rate and attributed part of the change to distracted commercial teams and weaker execution, while saying it has not lost major blocks of…
• Supply Chain ConstraintsImportance 26 · Surprise 24
  Peripheral Vascular results were affected by an ongoing supply disruption, although management said the business improved sequentially and teams made meaningful progress restoring supply during the quarter. Management…
• Shoulder Product AdoptionImportance 26 · Surprise 24
  Management said upper-extremity growth remains strong and described shoulder replacement as a faster-growing market than hips and knees, supported by improved patient outcomes and growing adoption. Stryker’s Tornier…
• Vascular Share RecoveryImportance 26 · Surprise 24
  Management characterized any share losses during the interim disruption in the Vascular business as temporary and believes it can win that business back. It expects to return to an offensive commercial posture. The…
• Gross Margin DriversImportance 24 · Surprise 14
  Adjusted gross margin was 65.4% in Q3 2026, up 40 basis points from Q3 2025. Management attributed the improvement to a net tariff benefit and operational efficiencies. Adjusted operating margin reached 26.2% of sales,…
• Pricing and Market CompetitionImportance 24 · Surprise 14
  Management expects modest pricing across Stryker’s portfolio, with positive price likely coming more from MedSurg and slightly negative price in ortho. The company is seeking to hold as much orthopaedic pricing as…
• Geographic Market CommentaryImportance 20 · Surprise 24
  Management says Europe and the Middle East remained soft in hips and knees, citing regional disruption, strike-related delays, and government funding decisions. International Orthopaedics growth was supported by Knees,…
• Robotic Surgery Market AdoptionImportance 20 · Surprise 24
  Management sees the largest opportunity for the Versius robotic system in converting procedures currently performed laparoscopically or through open surgery to robotic surgery. It said the system’s modular design and…
• Mako Robotics CompetitionImportance 13 · Surprise 6
  Management declined to assess a competitor’s Monogram product before it reaches the marketplace, but said Stryker believes Mako remains a winning platform. It highlighted Mako’s multiple applications on a single robot…